Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Consolidated Net Income (2016 - 2025)

Historic Consolidated Net Income for Ligand Pharmaceuticals (LGND) over the last 13 years, with Q3 2025 value amounting to $117.3 million.

  • Ligand Pharmaceuticals' Consolidated Net Income changed N/A to $117.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.6 million, marking a year-over-year change of. This contributed to the annual value of -$4.0 million for FY2024, which is 14216.22% down from last year.
  • Ligand Pharmaceuticals' Consolidated Net Income amounted to $117.3 million in Q3 2025.
  • Over the past 5 years, Ligand Pharmaceuticals' Consolidated Net Income peaked at $117.3 million during Q3 2025, and registered a low of -$42.5 million during Q1 2025.
  • For the 5-year period, Ligand Pharmaceuticals' Consolidated Net Income averaged around -$33923.1, with its median value being -$4.7 million (2021).
  • In the last 5 years, Ligand Pharmaceuticals' Consolidated Net Income soared by 8068.87% in 2021 and then tumbled by 13603.29% in 2022.
  • Ligand Pharmaceuticals' Consolidated Net Income (Quarter) stood at -$2.2 million in 2021, then tumbled by 32.75% to -$3.0 million in 2022, then skyrocketed by 43.58% to -$1.7 million in 2023, then crashed by 1767.15% to -$31.1 million in 2024, then surged by 477.23% to $117.3 million in 2025.
  • Its last three reported values are $117.3 million in Q3 2025, $4.8 million for Q2 2025, and -$42.5 million during Q1 2025.